Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Updated policy on proton beam radiation therapy

September 19, 2018

Independence is updating our policy on proton beam radiation therapy for certain commercial members to reflect changes in coverage criteria. Medical Policy #09.00.49j: Proton Beam Radiation Therapy was posted as a Notification on July 3, 2018, and will go into effect October 1, 2018. Note: This policy applies only to members of self-funded groups for whom eviCore?s Radiation Therapy Services program are not applicable.

Changes to coverage criteria

Below is an outline of the changes to our coverage criteria.

Medically Necessary indications

Proton beam radiation therapy is considered medically necessary and, therefore, covered for any of the following tumors:

  • chordomas and chondrosarcomas of the base of the skull, localized and in the postoperative setting
  • uveal melanoma, when proton beam radiation therapy is considered preferential compared to brachytherapy
  • localized unresectable hepatocellular carcinoma (HCC)
  • stage IIA seminoma
Not Medically Necessary indications

Proton beam radiation therapy is considered not medically necessary and, therefore, not covered for the treatment of the following tumors because current evidence indicates that proton beam radiation therapy is no more effective than other forms of radiation therapy (e.g., intensity-modulated radiation therapy [IMRT]):

  • previously untreated prostate cancer
  • head and neck cancer (not including the brain)
  • preoperative and definitive treatment of esophageal cancer
Experimental/Investigational indications

Proton beam radiation therapy is considered experimental/investigational and, therefore, not covered for all other indications, including the following, because the safety and/or effectiveness of this service cannot be established by review of the available published peer-reviewed literature:

  • in the treatment of prostate cancer after prostatectomy
  • when delivered in an ablative manner (i.e., stereotactic body radiation therapy [SBRT])
  • in combination with photon therapy for any tumor

For more information

To view the Notification for this policy, visit our Medical Policy Portal and select Accept and Go to Medical Policy Online. Then select Commercial under Active Notifications.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.